(Reuters) - The Novartis investment is the latest example of big pharma's growing interest in vaccines, a business previously thought of as low-growth and low-margin but which is being transformed by recent hi-tech innovations.
Switzerland's Novartis, Europe's third-largest drugmaker by sales, will buy 4.8 million new Intercell shares from a capital increase for 150 million euros, or 31.25 euros each. Its stake in Intercell will rise to 16 percent from 6 percent.
Read more at Reuters.com Hot Stocks News
Switzerland's Novartis, Europe's third-largest drugmaker by sales, will buy 4.8 million new Intercell shares from a capital increase for 150 million euros, or 31.25 euros each. Its stake in Intercell will rise to 16 percent from 6 percent.
Read more at Reuters.com Hot Stocks News
No comments:
Post a Comment